Compare Davita Inc (DVA) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Schwab US Dividend Equity ETF — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while Schwab US Dividend Equity ETF trades at $32.23. Which is the better fit depends on your goals.
| DVA | SCHD | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $235.71 | $32.83 |
52-Week Low | $103.87 | $26.38 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
SCHD trades at $32.56, up 0.49% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has recently underperformed the S&P 500 but shows strength in dividend-focused holdings, with nearly 30 components doubling the index's YTD return. A dividend of $0.25 is scheduled for June 2026, reinforcing its income appeal amid sideways price action since May.
Outlook remains favorable for income investors due to SCHD's high yield and dividend growth history, though competition from rising Treasury yields presents a risk. The ETF's low fee and quality stock selection support long-term wealth building, but market rotation away from value stocks could limit near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
